Month: September 2023

Zapp EV partners with leading financial services firm Younited SA to offer customers the innovative Younited Pay finance solution ahead of Zapp’s first i300 customer deliveries later this year Younited Pay provides a flexible finance solution to over one million customers across Europe, offering a simple, automated application process and instant credit approval The partnership puts in place another key pillar of Zapp’s industry-transforming customer offering as it nears the debut of the i300 Carbon Launch Edition urban electric motorcycleLONDON, Sept. 12, 2023 (GLOBE NEWSWIRE) — Zapp Electric Vehicles Group Limited (Nasdaq: ZAPP) (“Zapp EV”, or the “Company”), owner of Zapp, the British electric vehicle brand on a mission to revolutionise personal urban mobility, has partnered with Paris-based fintech firm Younited SA (“Younited”)...

Dovre Group Plc                            Press Release                      September 12, 2023, at 9 am Dovre Group awarded frame agreement with The Norwegian Ministry of Finance Dovre Group Consulting and Institute of Transport Economics together with Dovre Group Energy have been awarded a frame agreement with The Norwegian Ministry of Finance for supply of external quality assurance for large public projects in Norway. The agreement runs from September 2023 and has a duration of two years with an option for two additional years. «We are very proud to have been awarded this contract with The Norwegian Ministry of Finance», says Stein Berntsen, Head of Dovre Group Consulting. «It confirms our position as a recognised independent adviser to the owners of some of the largest and most complex projects in Norway». Dovre has had similar frame...

Horizontal Infill Drilling Program UpdateProspera has completed the drilling of four horizontal wells of the ten well multi-pad infill drill program.CALGARY, Alberta, Sept. 12, 2023 (GLOBE NEWSWIRE) — Prospera Energy Inc. (“Prospera” or the “Company”) (TSX.V: PEI, OTC: GXRFF, FRA: OF6B, OF6B.SG, OF6B.F, OF6B.BE).Prospera has completed the drilling of four horizontal wells of the ten well multi-pad infill drill program. These wells encountered structure and pay as expected with excellent oil show throughout the pay. The drilling technique tweaked from the pilot wells were executed efficiently and ahead of schedule. High praises to Lasso Drilling Corporation for the effective synergy with Prospera to attain efficiency. These drilled horizontals are being completed and tied-in to existing infrastructure. Turnaround time...

MACAU, Sept. 12, 2023 (GLOBE NEWSWIRE) — Nature Wood Group Limited (the “Company” or “Nature Wood”), a global leading vertically-integrated forestry company that focuses on FSC business operations, today announced the pricing of its initial public offering (the “Offering”) of 750,000 American Depositary Shares (“ADS”) at a price to public of US$9 per ADS for the total offering size of US$6.75 million, assuming the underwriters do not exercise their over-allotment option to purchase additional ADSs. Each ADS represents eight ordinary shares of the Company. The ADSs will begin trading on September 12, 2023, U.S. Eastern time, on the Nasdaq Capital Market under the symbol “NWGL”. The Offering is expected to close on September 14, 2023, subject to customary closing conditions. The Company has granted the underwriters the right to purchase...

TUCSON, AZ, Sept. 11, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Titan NRG, Inc. (“Titan NRG” OTC: TTNN), a leader in downstream energy and transportation through its wholly-owned subsidiaries, announces that its Board of Directors has approved a share repurchase program with authorization to purchase up to 3,000,000 shares of its preferred and/or common stock through September 1, 2024. Titan NRG’s commitment to its stock buyback program is a strategic move that will have a positive impact on the company’s future. The company will be looking to purchase up to 3,000,000 shares of certain preferred and common shares over the next year. Titan NRG aims to reduce the potential dilution that could occur in the future, sending a clear signal of its commitment to shareholders. This proactive approach demonstrates...

TORONTO, Sept. 11, 2023 (GLOBE NEWSWIRE) — Clip Money Inc. (TSX-V: CLIP) (OTCQB: CLPMF) (“Clip Money” or the “Company”), a company that operates a multi-bank self-service deposit system for businesses, is pleased to announce a non-brokered private placement of common shares in the capital of the Company (the “Common Shares ”) at a price of CDN$0.23 per Common Share (the “Equity Price”) for gross proceeds of approximately US$4,900,000 (the “Equity Financing”). The Equity Price was reserved with the TSX Venture Exchange on September 5, 2023. Separately, Clip is also pleased to announce a non-brokered private placement of secured convertible notes of the Company for gross proceeds of US$6,100,000 (the “Convertible Notes Financing”, together with the Equity Financing, the “Financings”). The lead subscriber under the Financings is a...

NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. CymaBay is selling 12,551,080 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 583,771 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $17.13 per share, and the pre-funded warrants are being sold at a public offering price of $17.1299 per underlying share. The gross offering proceeds to CymaBay from this offering are expected to be approximately...

Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision expected by mid-November BRISBANE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the recently completed submission of the rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG). The Company anticipates the FDA will file the rolling NDA by mid-November 2023. pLGG...

–Clover launches AdimFlu-S (QIS) in mainland China, the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older —  –Second commercialized product strengthens Clover’s leading respiratory vaccine franchise and financial profile–  SHANGHAI, China, Sept. 12, 2023 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the launch of AdimFlu-S (QIS) in mainland China, where it is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older. To date, the QIS vaccine has been listed in 26 provinces and municipalities...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in China. The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma (“R/R FL”). The primary objective is to evaluate the objective response rate (“ORR”) of tazemetostat for the treatment of patients with R/R FL whose disease harbor EZH21 mutations (Cohort 1). The secondary objectives included duration of response (“DoR”), progression-free survival (PFS), and overall survival (OS) of tazemetostat for the treatment of R/R FL patients whose disease...